What is the 13F Pro Quality Score for SGHT?

13F Pro ranks Sight Sciences, Inc. (SGHT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SGHT's current score at https://13fpro.ai/research/SGHT (free sign-up required for the full ranking).

Which hedge funds own the most SGHT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SGHT include Long Focus Capital Management,, BlackRock,, Pathstone Holdings,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SGHT as soon as new 13F filings post.

Where does 13F Pro source SGHT data?

All Sight Sciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Sight Sciences, Inc. files with the SEC under CIK 1531177. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SGHT in?

Sight Sciences, Inc. (SGHT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SGHT research updated on 13F Pro?

SGHT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sight Sciences, Inc.(SGHT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1531177 SGHT stock profile & AI dashboard →

13F Pro Quality Score

17.4/100

Rank #2,720 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

23.3/100

Profitability

9.9/100

Balance Sheet

4.7/100

Earnings Quality

30.0/100

Free Cash Flow

9.6/100

Institutional Flow

87.3/100

Revenue Scale

14.7/100

Dilution Risk

11.2/100

SGHT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Sight Sciences, Inc. (SGHT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SGHT at 17.4/100 on a 32-signal composite quality model, placing it at rank #2,720 of 2,879 stocks — the bottom half of the AI-ranked universe. SGHT scores in the top quartile across institutional flow (87.3). Areas of concern include balance sheet strength (4.7) and free cash flow (9.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Sight Sciences, Inc. reports quarterly revenue of $19.7M, net income of $-13.0M, free cash flow of $-7.1M. Top institutional holders of SGHT by reported 13-F value include Long Focus Capital Management,, BlackRock,, Pathstone Holdings,, based on the most recent SEC filings. SGHT trades on the Nasdaq exchange and files with the SEC under CIK 1531177. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGHT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sight Sciences, Inc. directly from SEC EDGAR. Sight Sciences, Inc.'s 13F Pro composite quality score has ranged between 8 and 50 since 2022, currently 17.4 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Sight Sciences, Inc.

Quirks, history, and lore behind SGHT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the low tens of millions of dollars — this is a growth-stage company that spends heavily on sales and R&D while still working toward consistent profitability.
3
The History
Founded in the 2000s, the company spent years developing minimally invasive devices before going public on Nasdaq around 2021.
4
The Secret
Its entire focus is on eye disease — specifically reducing intraocular pressure without the hassle of daily eye drops or invasive surgery.
5
The Lore
Its flagship procedure uses a tiny implant called OMNI to treat glaucoma by targeting multiple drainage pathways in the eye at once — surgeons love that it's a one-and-done approach.
6
The Giveaway
The name says it all: a company dedicated to the science of sight, making tools that help ophthalmologists preserve patients' vision — one tiny eye at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$19.7M

Net Income

Q1 2026

$-13.0M

Free Cash Flow

Q1 2026

$-7.1M

D/E Ratio

Q1 2026

0.75

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-3.1% YoY

$77.4MFY 2025

FY20 $27.6MFY21 $49.0MFY24 $79.9MFY25 $77.4M

Net Income

+25.4% YoY

$-38.4MFY 2025

FY20 $-34.7MFY21 $-63.0MFY24 $-51.5MFY25 $-38.4M

Operating Income

+26.6% YoY

$-37.1MFY 2025

FY20 $-32.2MFY21 $-51.5MFY24 $-50.5MFY25 $-37.1M

EPS (Diluted)

+28.2% YoY

$-0.74FY 2025

FY20 —FY21 $-2.36FY24 $-1.03FY25 $-0.74

Total Assets

-19.3% YoY

$115.3MFY 2025

FY20 $72.8MFY21 $280.2MFY24 $142.8MFY25 $115.3M

Total Debt

+2.4% YoY

$40.3MFY 2025

FY20 $32.0MFY21 $32.7MFY24 $39.4MFY25 $40.3M

Op. Cash Flow

-32.9% YoY

$-29.7MFY 2025

FY20 $-32.2MFY21 $-52.5MFY24 $-22.4MFY25 $-29.7M

Metric	FY 2025	FY 2024	FY 2021	FY 2020
Revenue	$77.4M -3.1%	$79.9M +63.1%	$49.0M +77.1%	$27.6M
Net Income	$-38.4M +25.4%	$-51.5M +18.2%	$-63.0M -81.5%	$-34.7M
Operating Income	$-37.1M +26.6%	$-50.5M +1.8%	$-51.5M -59.9%	$-32.2M
EPS (Diluted)	$-0.74 +28.2%	$-1.03 +56.4%	$-2.36	—
Total Assets	$115.3M -19.3%	$142.8M -49.0%	$280.2M +284.8%	$72.8M
Total Debt	$40.3M +2.4%	$39.4M +20.5%	$32.7M +2.2%	$32.0M
Operating Cash Flow	$-29.7M -32.9%	$-22.4M +57.5%	$-52.5M -63.3%	$-32.2M

AI Insight: SGHT Ratio Trends

Q1 2026 margin collapse reverses Q4 2025's apparent recovery, with OpMargin plunging to -63.0% and ROIC deteriorating to -52.6%.

• Operating margin swung from -18.0% in Q4 2025 to -63.0% in Q1 2026, erasing the sharpest improvement seen in the dataset.

• ROE deepened to -96.3% in Q1 2026 from -26.0% in Q4 2025, the worst reading across all periods shown.

• D/E ratio has risen steadily from 0.33 in Q2 2024 to 0.75 in Q1 2026, signaling increasing leverage over the period.

• Q4 2025 showed a genuine sequential improvement—OpMargin improved from -79.2% in Q1 2025 to -18.0%—suggesting strong seasonality.

⚠ Q1 seasonality appears severe; whether Q2 2026 rebounds toward Q4 2025 levels is the key inflection to monitor.

⚠ ROIC hit -52.6% in Q1 2026, worse than any prior quarter, raising questions about capital efficiency as leverage rises.

⚠ D/E at 0.75 is the highest on record here; continued cash burn with rising debt could pressure the balance sheet.

Get alerted when SGHT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sight Sciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SGHT

Long Focus Capital Management, LLC
$13.5M3,594,100 sh
BlackRock, Inc.
$10.7M2,831,932 sh
Pathstone Holdings, LLC
$9.0M2,397,332 sh
Americana Partners, LLC
$6.3M1,679,017 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.5M1,452,690 sh
B Group, Inc.
$3.7M970,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.5M915,444 sh
STATE STREET CORP
$3.1M835,028 sh
Qube Research & Technologies Ltd
$1.9M497,508 sh
DIMENSIONAL FUND ADVISORS LP
$1.3M341,681 sh

Fund	Value	Shares
Long Focus Capital Management, LLC	$13.5M	3,594,100
BlackRock, Inc.	$10.7M	2,831,932
Pathstone Holdings, LLC	$9.0M	2,397,332
Americana Partners, LLC	$6.3M	1,679,017
VANGUARD CAPITAL MANAGEMENT LLC	$5.5M	1,452,690
B Group, Inc.	$3.7M	970,000
GEODE CAPITAL MANAGEMENT, LLC	$3.5M	915,444
STATE STREET CORP	$3.1M	835,028
Qube Research & Technologies Ltd	$1.9M	497,508
DIMENSIONAL FUND ADVISORS LP	$1.3M	341,681

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SGHT on your watchlist

Track score changes the day Sight Sciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SGHT a good stock to buy?

13F Pro's AI-powered analysis of Sight Sciences, Inc. (SGHT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SGHT are available on the SGHT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SGHT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SGHT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sight Sciences, Inc.'s investment landscape.